Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Sintilimab in Cisplatin-Intolerant LA SCCHN
NCT05831930Phase 1Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nimotuzumab and sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Complete Remission Rate at 2 years. Started Jan 2023; status: recruiting.
02
Drugs
nimotuzumabsintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05831930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831930.